InsidersTradesSigma
Total declarations
Companies
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
6
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-58.8%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Ehrlich Christopher B, Chief Executive Officer. Insider active across 3 companies, notably eFFECTOR Therapeutics, Inc.. Aggregated, 10 reports have been recorded. Breakdown: 6 buys · 0 sell. Total volume traded: €198. History available since 25 August 2021. The latest transaction was filed on 4 October 2022 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Ehrlich Christopher B
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations10 total
5,312,983 sharesCommon StockSEC:0001213900-24-084830:0
1,125,000 sharesCommon StockSEC:0001213900-24-015026:0
346 shares@ US$0.570.2% of flowCommon StockSEC:0001209191-22-052933:0
Canonical exit: 2 Jan 2023 (T+90)
18,867 shares@ €0.571515.5% of flowCommon StockSEC:0001209191-22-051313:0
Canonical exit: 25 Dec 2022 (T+90)
2,000 shares@ €3.915511.3% of flowCommon StockSEC:0001209191-22-011731:0
Canonical exit: 15 May 2022 (T+90)
1,000 shares@ €4.29966.2% of flowCommon StockSEC:0001209191-22-008529:0
Canonical exit: 9 May 2022 (T+90)
5,000 shares@ €4.557532.8% of flowCommon StockSEC:0001209191-22-007349:0
Canonical exit: 4 May 2022 (T+90)
5,000 shares@ €4.716533.9% of flowCommon StockSEC:0001209191-22-005721:0
Canonical exit: 27 Apr 2022 (T+90)
36,733 shares@ US$10.00100.0% of flowClass A common stockSEC:0000899243-21-039941:0
142,168 shares0Common StockSEC:0001209191-21-053731:0
10 of 10 declarations
About Ehrlich Christopher B
Ehrlich Christopher B is Directeur Général. He has 10 filings in total, and across the sampled recent filings, buys amount to EUR 198 and sells to EUR 0, over the period from 2021-08-27 to 2024-10-02. The companies listed are eFFECTOR Therapeutics, Inc., CERO THERAPEUTICS HOLDINGS, INC. and Phoenix Biotech Acquisition CORP.
